A carregar...

Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR-tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less tox...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Ther Med
Main Authors: WATANABE, HIROKO, TAMURA, TOMOHIRO, KAGOHASHI, KATSUNORI, TAKAYASHIKI, NORIO, KURISHIMA, KOICHI, SATOH, HIROAKI, HIZAWA, NOBUYUKI
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487036/
https://ncbi.nlm.nih.gov/pubmed/26170967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!